1
|
Atkinson PJ, Stevenson M, O'Handley R, Nielsen T, Caraguel CGB. Temperature-bounded development of Dirofilaria immitis larvae restricts the geographical distribution and seasonality of its transmission: case study and decision support system for canine heartworm management in Australia. Int J Parasitol 2024; 54:311-319. [PMID: 38447815 DOI: 10.1016/j.ijpara.2024.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 01/19/2024] [Accepted: 02/29/2024] [Indexed: 03/08/2024]
Abstract
Dirofilaria immitis is the causative agent of canine heartworm disease. We used the established heartworm development unit (HDU) principle to map the extrinsic incubation period (EIP) of D. immitis in Australia using historical weather data from 2013-2022. We found weather conditions suitable for EIP completion showed substantial seasonality and geographical variability. Whilst a considerable percentage of the Australian territory showed suitable weather conditions to always support EIP completion (17%), only 2.7% of the 2021 Australian human population lived in this region. Therefore, 97% of the population lived in an area that changed its EIP suitability within the study period. EIP completion is required prior to D. immitis transmission, meaning that infection risk of D. immitis is seasonal and location-dependent, being disrupted each year for most of the human population's dogs. We developed an online, open access tool allowing us to visualise EIP completion across Australia historically and in near real-time. We aim to support veterinarians to make risk-based recommendations for dirofilariosis prevention by using the tool, available at https://heartworm-mapping.adelaide.edu.au/shiny/.
Collapse
Affiliation(s)
- Peter J Atkinson
- School of Animal and Veterinary Sciences, Faculty of Sciences, Engineering and Technology, The University of Adelaide, South Australia, 5371, Australia.
| | - Mark Stevenson
- Melbourne Veterinary School, Faculty of Science, The University of Melbourne, Parkville, Victoria 3010, Australia
| | - Ryan O'Handley
- School of Animal and Veterinary Sciences, Faculty of Sciences, Engineering and Technology, The University of Adelaide, South Australia, 5371, Australia
| | - Torben Nielsen
- School of Animal and Veterinary Sciences, Faculty of Sciences, Engineering and Technology, The University of Adelaide, South Australia, 5371, Australia
| | - Charles G B Caraguel
- School of Animal and Veterinary Sciences, Faculty of Sciences, Engineering and Technology, The University of Adelaide, South Australia, 5371, Australia
| |
Collapse
|
2
|
Still MB, Tedesco D, Hawkins C, Putnam H. Improving access to melarsomine therapy: treating canine heartworm infection in a high-volume, outpatient community clinic setting. Parasit Vectors 2024; 17:119. [PMID: 38459570 PMCID: PMC10924336 DOI: 10.1186/s13071-024-06153-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Accepted: 01/22/2024] [Indexed: 03/10/2024] Open
Abstract
BACKGROUND Models that provide high-quality veterinary care for more affordable prices are emerging, but not well documented outside of wellness and preventative care. Effective treatment guidelines for heartworm disease have been developed by the American Heartworm Society; however, not all owners are able to access treatment due to the high costs associated with sick and emergency care services. METHODS To increase access to high-quality adulticidal treatment of canine heartworm disease, we developed and implemented a technician-leveraged heartworm treatment protocol for high-volume, outpatient community clinic settings based on the American Heartworm Society guidelines. Modifications were few and included limited pre-treatment blood work, pre-injection sedation, post-injection pain medication, and a reduced exercise restriction period. We monitored retention rates for 556 dogs throughout treatment, evaluated treatment success (defined as no antigen detection 9 months post treatment) for patients that returned for post-treatment antigen testing, and reported on adverse reactions and therapy adherence throughout treatment. RESULTS Of the patients that began adulticide therapy, 539/556 (97%) successfully completed the three-injection series. No microfilariae were detected in 99% (428/433) of those who returned for post-injection microfilaria testing. Among those that returned for or reported the results of post-injection antigen testing, no antigen was detected for 99% (245/248) and no microfilariae were detected for 99.5% (200/201). During the course of treatment, 483/539 (90%) of patients experienced at least one adverse reaction, with the most frequently reported types being behavioral and injection site reactions. 25/539 (4.6%) of owners sought additional medical care for adverse reactions at some point during the treatment course. The overall mortality rate was 1.3% (7/556). CONCLUSIONS This study represents the first evaluation of a heartworm treatment protocol optimized for implementation in a high-volume, outpatient community clinic setting. Our findings align with those previously reported in private practice or tertiary referral centers, illustrating that through the inclusion of pre-treatment blood work, employing short-acting or reversible sedatives, ensuring proper analgesia, minimizing the use of ancillary diagnostics, reducing the duration of in-clinic monitoring while focusing on outpatient care, and maximizing technician involvement, we can deliver effective and safe melarsomine therapy at a more affordable cost to pet owners.
Collapse
Affiliation(s)
- Meghan B Still
- Research, Data, and Analytics, Emancipet, Austin, TX, USA
| | - Dana Tedesco
- Clinical Services Group, Emancipet, Austin, TX, USA
| | - Christina Hawkins
- Community Medicine, American Society for the Prevention of Cruelty to Animals, New York, NY, USA
| | - Holly Putnam
- Clinical Services Group, Emancipet, Austin, TX, USA.
| |
Collapse
|
3
|
Mwacalimba K, Sears D, Brennan C, Poulsen Nautrup B, Sheehy J, Smith K, Adolph C. Retrospective analyses of heartworm (Dirofilaria immitis) disease and ectoparasite preventive medication compliance in veterinary practices in the USA. Parasit Vectors 2023; 16:149. [PMID: 37106437 PMCID: PMC10142219 DOI: 10.1186/s13071-023-05735-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Accepted: 03/12/2023] [Indexed: 04/29/2023] Open
Abstract
BACKGROUND Compliance failure with administration of heartworm (HW) disease preventives has been reported as the main contributor to HW disease incidence in medicalized dogs. This study aimed to evaluate purchase compliance with different canine HW preventive products in the USA. METHODS Anonymized transaction data from clinics throughout the USA served as the basis for two retrospective analyses. We first examined the monthly equivalent doses of HW preventive purchases from clinics that had implemented extended-release moxidectin injectables ProHeart® 6 (PH6) and/or ProHeart® 12 (PH12) compared to clinics that prescribed monthly HW preventatives (MHWP) only. In the second analysis, the purchase compliance in practices that dispensed only flea and tick (FT) and HW products separately but did not dispense combination products (dual-therapy practices) was compared to the purchase compliance with the combination product Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets), purchased in clinics having implemented combination therapy in their formulary (combination-therapy practices). In both analyses, the numbers of monthly doses dispensed annually per dog were calculated. RESULTS Transaction data from 3,539,990 dogs in 4615 practices were included in the first analysis. In dogs administered PH12 or PH6, the numbers of monthly equivalent doses were 12 and 8.1, respectively. In both clinic types, the average annual number of MHWP doses totaled 7.3. In the second analysis, a total of 919 practices were identified as combination-therapy practices and 434 as dual-therapy-only practices. A total of 246,654 dogs (160,854 dogs in dual-therapy practices and 85,800 dogs in combination-therapy practices) were included in the calculation of the average annual number of monthly doses, which totaled 6.8 (HW preventive products) and 4.4 (FT products) in dual-therapy practices compared to 7.2 months for both FT and HW preventives with Simparica Trio® across both practice types. CONCLUSIONS The injectable HW preventive PH12 is the only product that provides 12 months of heartworm disease prevention in a single veterinarian-administered injection. When choosing a monthly preventive, the combination therapy was associated with a greater purchase compliance compared with FT and HW products being dispensed separately.
Collapse
Affiliation(s)
| | | | | | | | - Jenifer Sheehy
- Veterinary Professional Services, Zoetis, Parsippany, NJ, USA
| | - Kristine Smith
- Veterinary Professional Services, Zoetis, Parsippany, NJ, USA
| | | |
Collapse
|
4
|
Constantinoiu C, Croton C, Paterson MBA, Knott L, Henning J, Mallyon J, Coleman GT. Prevalence of canine heartworm infection in Queensland, Australia: comparison of diagnostic methods and investigation of factors associated with reduction in antigen detection. Parasit Vectors 2023; 16:63. [PMID: 36765417 PMCID: PMC9921331 DOI: 10.1186/s13071-022-05633-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Accepted: 12/22/2022] [Indexed: 02/12/2023] Open
Abstract
BACKGROUND The prevalence of Dirofilaria immitis infection in dogs is increasing globally and spreading into new areas. Prevalence of dirofilariosis in the state of Queensland, Australia, was as high as 90% before the introduction of macrocyclic lactones. Limited research on prevalence of D. immitis infection in dogs in Queensland has been reported in the last 30 years. Antigen testing is the most common method for detection of dirofilariosis but its accuracy is reduced by antigen getting trapped (blocked antigen) in immune complexes (ICs). The objectives of this research were to determine the prevalence of D. immitis infection in dogs from two geographical areas (Brisbane and Townsville) in Queensland, to determine the extent to which blocked antigen affects the validity of antigen testing, and to explore whether this was associated with microfilaraemia, location, age or sex. METHODS Blood samples from Brisbane (sub-tropical climate) and Townsville (tropical climate) shelter dogs were evaluated for the presence of D. immitis antigen before (conventional antigen testing, CAT) and after dissociation of ICs by heat treatment (antigen testing after heat treatment, ATHT), using a commercially available test. Microfilariae were detected using modified Knott's test (MKT). Test proportions were compared with McNemar's test and the association between antigen test-discordant results (positive for antigen after dissociation of ICs) and microfilaraemia, location, sex and age was modelled using logistic regression. RESULTS Dirofilaria immitis prevalence in dogs from Townsville (22% by CAT, 32.1% by ATHT and 16.7% by MKT) was significantly higher than in dogs from Brisbane (1.1% by CAT and MKT and 1.7% by ATHT) [Formula: see text]. Dissociation of ICs allowed detection of significantly more D. immitis infected dogs than either conventional antigen testing or microfilariae detection, or the combined antigen and microfilariae detection [Formula: see text]. The odds of dogs being positive for antigen after dissociation of ICs were significantly higher for microfilaraemic, 3-4-year-old female dogs from Townsville. CONCLUSIONS The high prevalence of infection with D. immitis in dogs from Townsville poses a health risk for local susceptible host species, including humans. Dissociation of ICs increases antigen detection and should be considered in dogs suspected of D. immitis infection but negative on routine testing.
Collapse
Affiliation(s)
| | - Catriona Croton
- grid.1048.d0000 0004 0473 0844University of Southern Queensland, Toowoomba, QLD Australia ,grid.1003.20000 0000 9320 7537The University of Queensland, Gatton, QLD Australia
| | - Mandy B. A. Paterson
- Royal Society for the Prevention of Cruelty to Animals, Brisbane, QLD Australia ,grid.1003.20000 0000 9320 7537The University of Queensland, Gatton, QLD Australia
| | - Lyn Knott
- grid.1003.20000 0000 9320 7537The University of Queensland, Gatton, QLD Australia
| | - Joerg Henning
- grid.1048.d0000 0004 0473 0844University of Southern Queensland, Toowoomba, QLD Australia ,grid.1003.20000 0000 9320 7537The University of Queensland, Gatton, QLD Australia
| | - John Mallyon
- grid.1003.20000 0000 9320 7537The University of Queensland, Gatton, QLD Australia
| | - Glen T. Coleman
- grid.1048.d0000 0004 0473 0844University of Southern Queensland, Toowoomba, QLD Australia ,grid.1003.20000 0000 9320 7537The University of Queensland, Gatton, QLD Australia
| |
Collapse
|
5
|
Power RI, Šlapeta J. Exploration of the sensitivity to macrocyclic lactones in the canine heartworm (Dirofilaria immitis) in Australia using phenotypic and genotypic approaches. Int J Parasitol Drugs Drug Resist 2022; 20:145-158. [PMID: 36417831 PMCID: PMC9772245 DOI: 10.1016/j.ijpddr.2022.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2022] [Revised: 11/08/2022] [Accepted: 11/08/2022] [Indexed: 11/18/2022]
Abstract
Canine heartworm disease is a potentially deadly cardiopulmonary disease caused by the mosquito-borne filarial nematode Dirofilaria immitis. In Australia, the administration of macrocyclic lactone (ML) drugs has successfully reduced the prevalence of D. immitis infection. However, the recent re-emergence of D. immitis in dogs in Queensland, Australia and the identification of ML-resistant isolates in the USA poses an important question of whether ML-resistance has emerged in this parasite in Australia. The aim of this study was to utilise phenotypic and genotypic approaches to examine the sensitivity to ML drugs in D. immitis in Australia. To do this, we surveyed 45 dogs from Queensland and New South Wales across 3 years (2019-2022) for the presence of D. immitis infection using an antigen test, quantitative Modified Knott's test, and qPCR targeting both D. immitis and the D. immitis symbiont Wolbachia. A phenotype observed by utilising sequential quantification of microfilariae for 23/45 dogs was coupled with genetic testing of filtered microfilariae for SNPs previously associated with ML-resistance in isolates from the USA. Sixteen (16/45) dogs tested positive for D. immitis infection despite reportedly receiving 'rigorous' heartworm prevention for 12 months prior to the study, according to the owners' assessment. The phenotype and genotypic assays in this study did not unequivocally demonstrate the presence of ML-resistant D. immitis in Australia. Although the failure of 16 dogs to reduce microfilaremia by >90% after ML treatment was considered a suspect phenotype of ML-resistance, no genotypic evidence was discovered using the genetic SNP analysis. The traditional quantitative Modified Knott's test can be substituted by qPCR targeting D. immitis or associated Wolbachia endosymbiont DNA for a more rapid measurement of microfilariae levels. More definitive phenotypic evidence of resistance is critically needed before the usefulness of SNPs for the detection of ML-resistance in Australia can be properly assessed.
Collapse
Affiliation(s)
- Rosemonde Isabella Power
- Sydney School of Veterinary Science, Faculty of Science, University of Sydney, New South Wales, 2006, Australia
| | - Jan Šlapeta
- Sydney School of Veterinary Science, Faculty of Science, University of Sydney, New South Wales, 2006, Australia,The University of Sydney Institute for Infectious Diseases, New South Wales, 2006, Australia,Corresponding author. Sydney School of Veterinary Science, Faculty of Science, University of Sydney, New South Wales, 2006, Australia.
| |
Collapse
|
6
|
The compliance and revenue benefits of ProHeart Vs monthly heartworm disease preventives in the US. PLoS One 2022; 17:e0271058. [PMID: 35951635 PMCID: PMC9371284 DOI: 10.1371/journal.pone.0271058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2021] [Accepted: 06/22/2022] [Indexed: 11/19/2022] Open
Abstract
The aim of the current study was to understand how the canine heartworm disease preventive ProHeart® 12 (extended-release injectable moxidectin, PH 12), impacts heartworm preventive purchase compliance and veterinary practice revenue over time compared to monthly heartworm disease preventives. This was a preliminary observational purchase compliance and revenue study based on a retrospective review of transaction data from 4,615 general practices across the United States. The review period was from September 2018 to August 2020. Anonymous transaction records of over 13 million canine patients were analyzed. Of these, only 3.5 million (25.7%) patients purchased any heartworm preventive, as has been presented in other studies. Practices that implemented PH 12 demonstrated the most growth in canine heartworm prevention revenue, patients, and patient compliance levels during the 12-month observation period, compared to previous year. These practices saw year over year growth in percent patients receiving heartworm protection, as well as 10% and 15% growth in the proportion of preventive patients compliant for more than 6 months and 12 months respectively. In contrast, practices that did not bring on PH 12 and only dispensed monthly heartworm preventives saw a decline in the proportion of canine preventive patients that were compliant for more than 6 months. Similarly, PH 12 practices experienced 15% growth in preventive revenue, and practices that did not bring on PH 12 only experienced 3.9% growth in preventive revenue. PH 12 was single-handedly responsible for all growth in patients compliant for more than 6 months in this study. Growth in protection of canine patients with PH 12 proves a helpful tool where mitigation strategies have thus far failed to curb increasing canine heartworm disease prevalence in the US.
Collapse
|
7
|
Vercelli C, Bertolotti L, Gelsi E, Gazza C, Re G. Evaluation of Side Effects and Long-Term Protection of a Sustained-Release Injectable Moxidectin Formulation against Dirofilaria immitis Infection in Dogs: An Observational—In Field Multicentric Study. Vet Sci 2022; 9:vetsci9080408. [PMID: 36006323 PMCID: PMC9415797 DOI: 10.3390/vetsci9080408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 07/25/2022] [Accepted: 08/02/2022] [Indexed: 11/16/2022] Open
Abstract
Simple Summary The sustained-release moxidectin formulation of Afilaria SR is labelled to prevent Dirofilaria immitis infection in dogs for a period of six months. An observational—in field multicentric study was design to evaluate the tolerability and the long-term prevention of Afilaria SR in Italy. A total of 583 dogs were recruited from 2018 to 2021, receiving the drug annually and monitored by veterinary practitioners after each administration. Antigenic tests were performed 210, 365, 730, and 1095 days after the administration of the drug. None of the enrolled dogs was detected as positive, since it was possible to establish that 100% of protection was achieved. Afilaria SR was well tolerated since only the 13% of dogs demonstrated mild reaction in the injection site and only two dogs out of 583 demonstrated anaphylactoid or angioneurotic reactions. These data support the high prevention rate against Dirofilaria immitis disease in all enrolled dogs and indicate the high safety profile of the product, considering the low number and the low grade of side effects. Abstract The sustained-release moxidectin formulation Afilaria SR is a relatively new product and has been labelled to prevent Dirofilaria immitis infection in dogs for a six months-period. An observational, in field multicentric study was performed, aiming to evaluate the tolerability and the long-term prevention of Afilaria SR in Italy, a country where filariasis is endemic. The study was designed to include not less than 300 dogs, older than 6 months, of any breed. Side effects were recorded by veterinarians and antigenic tests were performed after 210, 365, 730, and 1095 days after the administration of the drug. A total of 583 dogs were recruited from 2018 to 2021 and all of them were negative with respect to antigenic tests at all time points, indicating that 100% of protection was achieved. Ranking of adverse reactions and correlation to patient features were analyzed using descriptive statistics and χ2 square test, respectively. Afilaria SR was well tolerated: 13% of dogs experienced mild reactions and only two dogs out of 583 (0.3%) demonstrated anaphylactoid/angioneurotic reactions, resolved administering corticosteroids. These data support that Afilaria SR prevented Dirofilaria immitis disease in all enrolled dogs and the low number and the low grade of side effects indicate the high safety profile of the product.
Collapse
Affiliation(s)
- Cristina Vercelli
- Department of Veterinary Science, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, TO, Italy
- Correspondence: ; Tel.: +39-011-670-9710
| | - Luigi Bertolotti
- Department of Veterinary Science, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, TO, Italy
| | - Elisa Gelsi
- Azienda Terapeutica Italiana A.T.I. s.r.l., Fatrogroup, Via Emilia, 285, 40064 Ozzano dell’Emilia, BO, Italy
| | - Carlo Gazza
- Azienda Terapeutica Italiana A.T.I. s.r.l., Fatrogroup, Via Emilia, 285, 40064 Ozzano dell’Emilia, BO, Italy
| | - Giovanni Re
- Department of Veterinary Science, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, TO, Italy
| |
Collapse
|
8
|
Macrocyclic lactone resistance in Dirofilaria immitis: risks for prevention of heartworm disease. Int J Parasitol 2021; 51:1121-1132. [PMID: 34717929 DOI: 10.1016/j.ijpara.2021.08.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 08/29/2021] [Accepted: 08/31/2021] [Indexed: 11/21/2022]
Abstract
Heartworm disease, caused by Dirofilaria immitis, can be lethal in dogs and cats. It is transmitted by mosquitoes, and occurs in many parts of the world. Prevention relies on macrocyclic lactones. Macrocyclic lactones used are ivermectin, selamectin, abamectin, eprinomectin, milbemycin oxime and moxidectin, administered at 30-day intervals during the transmission season. Some moxidectin formulations are long-acting injectables. In the USA, preventives are recommended throughout the year. Loss of efficacy of macrocyclic lactone preventives was reported in 2005 and proof of resistance in the USA was published a decade later. Understanding factors which promote resistance is important to maintain control. Factors important for resistance development are discussed. Better, inexpensive tests to confirm resistance are needed. Infection in animals under chemoprophylaxis per se does not imply resistance because lack of compliance in preventive use could be the reason. In vivo confirmation of resistance is expensive, slow and ethically questionable. A microfilariae suppression test can be a surrogate test, but requires a high dose of a macrocyclic lactone and repeated blood microfilaria counts 2-4 weeks later. DNA single nucleotide polymorphism markers have been successfully used. However, the specific genetic changes which cause resistance are unknown. Surveys to map and follow the extent of resistance are needed. Long acting mosquito repellants and insecticides can play a useful role. High dose rate formulations of moxidectin, coupled with mosquito biting mitigation may reduce transmission of resistant genotypes. Doxycycline, daily for 28 days, as anti-Wolbachia treatment, can reduce transmission and remove adult parasites. However, new classes of heartworm preventives are needed. While any preventive strategy must be highly effective, registration requirements for 100% efficacy may hinder development of useful new classes of preventives. Continued reliance on macrocyclic lactone preventives, when they do not work against resistant genotypes, will spread resistance, and allow for more disease.
Collapse
|